Phio Pharmaceuticals Corp., a clinical-stage siRNA biopharmaceutical company, has announced a recommendation from the Safety Monitoring Committee to advance its INTASYL PH-762 skin cancer clinical trial to the fifth dose escalation cohort. This decision follows a supportive safety profile in the fourth cohort, consisting of five patients, which showed no dose-limiting toxicities or serious adverse events. The Phase 1b clinical trial is focused on evaluating the safety and tolerability of PH-762 for treating cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. To date, 15 patients have been treated across the first four cohorts. Pathology results assessing the efficacy of PH-762 in the fourth cohort will be presented in the future. Enrollment for the expected final cohort is anticipated to be completed by the third quarter of 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.